📜对乙酰氨基酚置于potassium Carbonate体系中,用 异丙醇 作为反应溶剂,化学反应 11.0H,反应生成 普拉洛尔 参考文献:Redox‐neutral Selenium‐catalysed Isomerisation Of Para ‐hydroxamic Acids Into Para ‐aminophenols 标题:Redox‐neutral Selenium‐catalysed Isomerisation Of Para ‐hydroxamic Acids Into Para ‐aminophenols 摘要:Abstracta Selenium‐catalysed Para‐hydroxylation Of N‐aryl‐hydroxamic Acids Is Reported. Mechanistically,The Reaction Comprises An N−o Bond Cleavage And Consecutive Selenium‐induced [2,3]‐rearrangement To Deliver Para‐hydroxyaniline Derivatives. The Mechanism Is Studied Through Both 18O‐crossover Experiments As Well As Quantum Chemical Calculations. This Redox‐neutral Transformation Provides An Unconventional Synthetic Approach To Para‐aminophenols. DOI:10.1002/anie.202100801
专利号:US-9353057-B2 优先权日:2003-12-30 标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof 发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA 权利人:XENOPORT INC 摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.
专利号:US-10925977-B2 优先权日:2006-10-05 标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications 发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S 权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS 摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.
专利号:US-2008287407-A1 优先权日:2003-12-10 标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use 发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI 权利人:NITROMED INC 摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.
专利号:US-7708989-B2 优先权日:1999-10-29 标题 :Methods of treating vascular diseases characterized by nitric oxide insufficiency 发明人:LOSCALZO JOSEPH; VITA JOSEPH A; LOBERG MICHAEL D; WORCEL MANUEL 权利人:NITROMED INC 摘要:The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.
专利号:US-7384976-B2 优先权日:2001-05-02 标 题:Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use 发明人:GARVEY DAVID S 权利人:NITROMED INC 摘要:The invention describes novel compositions comprising nebivolol and/or at least one metabolite of nebivolol and at least one nitric oxide donor, and, optionally, at least one antioxidant or a pharmaceutically acceptable salt thereof, and/or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and/or at least one nitrosated compound used to treat cardiovascular diseases. The compounds and compositions of the invention can also be bound to a matrix. The nitric oxide donor is a compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating and/or preventing vascular diseases characterized by nitric oxide insufficiency; and for treating and/or preventing Raynaud's syndrome; and for treating and/or preventing cardiovascular diseases or disorders.
专利号:US-7339065-B2 优先权日:2003-07-21 标题 :Design and synthesis of optimized ligands for PPAR 发明人:AVERY MITCHELL A; PERSHADSINGH HARRIHAR A 权利人:BETHESDA PHARMACEUTICALS INC; UNIV MISSISSIPPI 摘要:This invention provides new chemical entities useful for treating a variety of clinical disorders including those that are influenced by the activity of peroxisome proliferator activated receptors (PPAR). The structures of the compounds and methods to design, make and use the compounds are provided. Compounds and methods for administering therapeutic compositions comprising the compounds in cases of the disease psoriasis are provided. An exemplary compound having the formula compound is 5adamantan-2-yl-pentanoic acid {2-[4-(2,4-dioxo-thiazolidin-5-yl-methyl)-phenoxy]-ethyl}-methyl-amide is provided.
1: Stewart MW, Clarke SW. Practolol-induced SLE-like syndrome. Proc R Soc Med. 1976 Jan;69(1):61-2. doi: 10.1177/003591577606900131. 2: Waycott JA. Practolol. Br J Hosp Med. 1978 Oct;20(4):496. 1(6060):529-30. 4: van der Meer J. Practolol (Eraldin) [Practolol (Eraldin)]. Ned Tijdschr Geneeskd. 1975 Jun 21;119(25):999-1000. Dutch. 28(2):119-28. doi: 10.1016/s0009-9260(77)80085-8. 1(8016):843. 1(21):664. 91(11):963-72. doi: 10.1017/s0022215100084632. 1(1):9-16. doi: 10.1016/0192-0561(79)90025-0. 8(4):229-31. 9(7):453-8. doi: 10.3109/00498257909038750. 10(5-6):336-41. doi: 10.2165/00003495-197510050-00003.
合成参考文献
摘要:Toho Igakkai Zasshi. Journal of Medical Society of Toho University., 20(126), 1973 摘要:Medical Journal of Australia., 1(44), 1975 摘要:Polish Journal of Pharmacology and Pharmacy., 25(145), 1973 参考文献:10.1111/j.0954-6820.1980.tb09674.x 摘要:Johansson BW. A Comparative Study of Cardioselective β‐Blockade and Diazepam in Patients with Acute Myocardial Infarction and Tachycardia. Journal of Internal Medicine. 1980 Jan 12;207(1-6):47–53. doi: 10.1111/j.0954-6820.1980.tb09674.x. 摘要:Folco GC, Omini C, Viganŏ T, Iantorno G, Berti F. Pharmacologic control of thromboxane A2 generation in lungs. Adv Prostaglandin Thromboxane Res. 1980;7():917–25.